Clinical trial NCT01287585 - References

Hepatocellular Carcinoma — Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Citation(s)

•   Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen C-J, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro GM, Harris WP, Chen Z, Hubner R, Meyer T, Bomalaski JS, Lin CC, Chao Y, Chen LZ
  2016. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). J Clin Oncol 34, 2016 (suppl; abstr 4017).

A Randomized, Double-Blind, Multi-Center Phase 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy

Details for clinical trial NCT01287585